Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Trastuzumab duocarmazine by Byondis for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Trastuzumab duocarmazine is under clinical development by Byondis and currently in Phase II for Human Epidermal Growth Factor Receptor 2...
Trastuzumab duocarmazine by Byondis for Metastatic Breast Cancer: Likelihood of Approval
Trastuzumab duocarmazine is under clinical development by Byondis and currently in Phase I for Metastatic Breast Cancer. According to GlobalData,...
Trastuzumab duocarmazine by Byondis for Ovarian Cancer: Likelihood of Approval
Trastuzumab duocarmazine is under clinical development by Byondis and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...
Trastuzumab duocarmazine by Byondis for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
Trastuzumab duocarmazine is under clinical development by Byondis and currently in Phase II for Human Epidermal Growth Factor Receptor 2...